GlobalData on MSN11h
Novartis reports Phase III efficacy and safety outcomes of SMA treatmentNovartis has reported positive efficacy and safety outcomes from its Phase III clinical programme for OAV101 IT (onasemnogene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback